Tema Etfs LLC Buys New Stake in Edwards Lifesciences Co. (NYSE:EW)

Tema Etfs LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 21,635 shares of the medical research company's stock, valued at approximately $1,602,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Crowley Wealth Management Inc. bought a new position in Edwards Lifesciences during the fourth quarter valued at $26,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at $30,000. Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth $54,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth $62,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Citigroup restated a "buy" rating and issued a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Piper Sandler raised their target price on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and a consensus target price of $80.20.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the transaction, the chief financial officer now directly owns 41,098 shares in the company, valued at approximately $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the sale, the vice president now directly owns 33,496 shares of the company's stock, valued at $2,514,879.68. The trade was a 4.29% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 67,692 shares of company stock valued at $4,822,074. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.11 during trading hours on Friday, reaching $74.68. 1,704,052 shares of the stock traded hands, compared to its average volume of 5,120,970. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $43.81 billion, a price-to-earnings ratio of 10.71, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a 50 day moving average price of $72.69 and a 200 day moving average price of $71.99. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $0.66 earnings per share. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.